| Literature DB >> 20807813 |
Ji-Heui Seo1, Lisa J Wood, Anupriya Agarwal, Thomas O'Hare, Collin R Elsea, Ian J Griswold, Michael W N Deininger, Akira Imamoto, Brian J Druker.
Abstract
CRKL (CRK-like) is an adapter protein predominantly phosphorylated in cells that express the tyrosine kinase p210(BCR-ABL), the fusion product of a (9;22) chromosomal translocation causative for chronic myeloid leukemia. It has been unclear, however, whether CRKL plays a functional role in p210(BCR-ABL) transformation. Here, we show that CRKL is required for p210(BCR-ABL) to support interleukin-3-independent growth of myeloid progenitor cells and long-term outgrowth of B-lymphoid cells from fetal liver-derived hematopoietic progenitor cells. Furthermore, a synthetic phosphotyrosyl peptide that binds to the CRKL SH2 domain with high affinity blocks association of endogenous CRKL with the p210(BCR-ABL) complex and reduces c-MYC levels in K562 human leukemic cells as well as in mouse hematopoietic cells transformed by p210(BCR-ABL) or the imatinib-resistant mutant T315I. These results indicate that the function of CRKL as an adapter protein is essential for p210(BCR-ABL)-induced transformation. ©2010 AACR.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20807813 PMCID: PMC2940946 DOI: 10.1158/0008-5472.CAN-10-0607
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701